These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36525530)

  • 1. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2023 Jul; 33(4):633-639. PubMed ID: 36525530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population.
    Tanaka Y; Okuda K; Takeuchi Y; Katayama K; Haji Y; Yamanishi Y; Tribanek M; Guimbal-Schmolck C; Takeuchi T
    Mod Rheumatol; 2023 Jul; 33(4):680-689. PubMed ID: 36053757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
    Schiff MH; Jaffe JS; Freundlich B
    Ann Rheum Dis; 2014 Aug; 73(8):1549-51. PubMed ID: 24728329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
    J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral methotrexate for the treatment of rheumatoid arthritis.
    Yazici Y; Bata Y
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
    Yadlapati S; Efthimiou P
    Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication.
    Kameda H; Yamaoka K; Yamanishi Y; Tada M; Koike R; Nakajima A; Fusama M; Fujii T
    Mod Rheumatol; 2023 Dec; 34(1):1-10. PubMed ID: 37819199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
    Bianchi G; Caporali R; Todoerti M; Mattana P
    Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
    Whittle SL; Hughes RA
    Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects and management of side effects of methotrexate in rheumatoid arthritis.
    Albrecht K; Müller-Ladner U
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S95-101. PubMed ID: 21044440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis.
    Islam MS; Haq SA; Islam MN; Azad AK; Islam MA; Barua R; Hasan MM; Mahmood M; Safiuddin M; Rahman MM; Osmany MF; Bari N; Rumki RS; Rashid FB
    Mymensingh Med J; 2013 Jul; 22(3):483-8. PubMed ID: 23982537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
    Huang RY; Pan HD; Wu JQ; Zhou H; Li ZG; Qiu P; Zhou YY; Chen XM; Xie ZX; Xiao Y; Huang QC; Liu L
    Phytomedicine; 2019 Apr; 57():403-410. PubMed ID: 30851515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.